Skip to main content
Erschienen in: Digestive Diseases and Sciences 7/2022

20.07.2021 | Original Article

Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study

verfasst von: Petra Anna Golovics, Lorant Gonczi, Jason Reinglas, Christine Verdon, Sheetal Pundir, Waqqas Afif, Gary Wild, Alain Bitton, Talat Bessissow, Peter L. Lakatos

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Optimal management of patients with ulcerative colitis (UC) requires the accurate, objective assessment of disease activity.

Aims

We aimed to determine how strong patient-reported outcomes, clinical scores and symptoms correlate with endoscopy and biomarkers for assessment of disease activity in patients with UC.

Methods

Consecutive patients with UC followed at the McGill University IBD Center and referred for endoscopy (surveillance or flare) were included prospectively between September 2018 and August 2020. Patient-reported outcome (PRO2), partial Mayo, Simple Clinical Colitis Activity Index (SCCAI), Mayo endoscopic subscore (MES) and Baron and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores were calculated. C-reactive protein (CRP) and fecal calprotectin (FCAL) were collected.

Results

A total of 171 patients with UC [age: 49(IQR:38–61) years, female: 46.2%, 57.3% extensive disease, 42.7% on biologicals] were included prospectively. Rectal bleeding (RBS), stool frequency (SF) subscore of 0, or total PRO2 remission (RBS0 and SF ≤ 1), partial Mayo (≤ 2) and SCCAI (≤ 2.5) remission were similarly associated with mucosal healing defined by MES (0 or ≤ 1), Baron (0 or ≤ 1) or UCEIS (≤ 3) scores in ROC analysis (AUC:0.93–0.72). There was a moderate-to-strong agreement between MES Baron and UCEIS (K = 0.91–0.41). A UCEIS of ≤ 3 was identified as the best cutoff to clinical or endoscopic remission. Agreement between CRP and clinical remission or endoscopic healing (MES/Baron) was poor (K ~ 0.2), while agreement between FCAL and RBS-PRO2 or MES/Baron/UCEIS was moderate to strong (K = 0.44–0.70).

Conclusions

Agreement between RBS, SF, PRO2, partial Mayo and SCCAI in predicting endoscopic healing was moderate to strong, while no clinically meaningful difference was found in accuracy across the scores and definitions. FCAL, but not CRP, was associated to clinical and endoscopic remission.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat De Dombal FT. Ulcerative colitis: definition, historical background, aetiology, diagnosis, naturel history and local complications. Postgrad Med J. 1968;44:684–692.CrossRef De Dombal FT. Ulcerative colitis: definition, historical background, aetiology, diagnosis, naturel history and local complications. Postgrad Med J. 1968;44:684–692.CrossRef
2.
Zurück zum Zitat Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483-489.e3.CrossRef Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483-489.e3.CrossRef
3.
Zurück zum Zitat Ferrante M, Vermeire S, Fidder H et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–225.CrossRef Ferrante M, Vermeire S, Fidder H et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–225.CrossRef
4.
Zurück zum Zitat Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.CrossRef Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.CrossRef
5.
Zurück zum Zitat Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.CrossRef Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.CrossRef
6.
Zurück zum Zitat Turner D, Ricciuto A, Lewis A et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies. IBD Gastroenterol 2021;160:1570–1583.CrossRef Turner D, Ricciuto A, Lewis A et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies. IBD Gastroenterol 2021;160:1570–1583.CrossRef
7.
Zurück zum Zitat Colombel JF, Keir ME, Scherl A et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66:2063–2068.CrossRef Colombel JF, Keir ME, Scherl A et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66:2063–2068.CrossRef
8.
Zurück zum Zitat Jharap B, Sandborn WJ, Reinisch W et al. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42:1082–1092.CrossRef Jharap B, Sandborn WJ, Reinisch W et al. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42:1082–1092.CrossRef
9.
Zurück zum Zitat Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-reported outcomes and endoscopic appearance of ulcerative colitis-a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:411–418.CrossRef Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-reported outcomes and endoscopic appearance of ulcerative colitis-a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:411–418.CrossRef
10.
Zurück zum Zitat Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.CrossRef Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.CrossRef
11.
Zurück zum Zitat Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRef
12.
Zurück zum Zitat Manginot C, Baumann C, Peyrin-Biroulet L. An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut. 2015;64:1181–1182.CrossRef Manginot C, Baumann C, Peyrin-Biroulet L. An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut. 2015;64:1181–1182.CrossRef
13.
Zurück zum Zitat Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.CrossRef Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.CrossRef
14.
Zurück zum Zitat Restellini S, Chao CY, Martel M et al. Clinical parameters correlate with endoscopic activity of ulcerative colitis: a systematic review. Clin Gastroenterol Hepatol. 2019;17:1265-1275.e8.CrossRef Restellini S, Chao CY, Martel M et al. Clinical parameters correlate with endoscopic activity of ulcerative colitis: a systematic review. Clin Gastroenterol Hepatol. 2019;17:1265-1275.e8.CrossRef
15.
Zurück zum Zitat Jairath V, Khanna R, Zou GY et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42:1200–1210.CrossRef Jairath V, Khanna R, Zou GY et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42:1200–1210.CrossRef
16.
Zurück zum Zitat Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89–92.CrossRef Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89–92.CrossRef
17.
Zurück zum Zitat Travis SPL, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–542.CrossRef Travis SPL, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–542.CrossRef
18.
Zurück zum Zitat Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis. 2018;50:353–359.CrossRef Jusué V, Chaparro M, Gisbert JP. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Dig Liver Dis. 2018;50:353–359.CrossRef
19.
Zurück zum Zitat D’Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.CrossRef D’Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.CrossRef
20.
Zurück zum Zitat Colombel J-F, Keir ME, Scherl A et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66:2063–2068.CrossRef Colombel J-F, Keir ME, Scherl A et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66:2063–2068.CrossRef
21.
Zurück zum Zitat Arai M, Naganuma M, Sugimoto S et al. The Ulcerative Colitis Endoscopic Index of Severity is useful to predict medium- to long-term prognosis in ulcerative colitis patients with clinical remission. J Crohns Colitis. 2016;10:1303–1309.CrossRef Arai M, Naganuma M, Sugimoto S et al. The Ulcerative Colitis Endoscopic Index of Severity is useful to predict medium- to long-term prognosis in ulcerative colitis patients with clinical remission. J Crohns Colitis. 2016;10:1303–1309.CrossRef
Metadaten
Titel
Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study
verfasst von
Petra Anna Golovics
Lorant Gonczi
Jason Reinglas
Christine Verdon
Sheetal Pundir
Waqqas Afif
Gary Wild
Alain Bitton
Talat Bessissow
Peter L. Lakatos
Publikationsdatum
20.07.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07178-w

Weitere Artikel der Ausgabe 7/2022

Digestive Diseases and Sciences 7/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.